Genentech

ACTEMRA

Manufacturer:

Genentech

Actemra HCPCS:

J3262

HCPCS Code Descriptor:

Injection, tocilizumab, 1 mg

Category:

J Code

Actemra NDCs:

50242-0137-01, 50242-0136-01, 50242-0143-01, 50242-0138-01, 50242-0135-01

Primary Type:

Immunology:Anti-TNF

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

50242-0137-01, 50242-0136-01, 50242-0135-01

About Actemra:

ACTEMRA is an Immunology:Anti-TNF drug manufactured by Genentech and administered via the Intravenous route of administration. The J Code: J3262 is aligned to the drug ACTEMRA.

ACCESS PRICING AND MORE BY REGISTERING

J3262 Added Date:

January 1, 2011

J3262 Effective Date:

January 1, 2011

J3262 Termination Date:

HCPCS Active

Actemra billing and coding information can be found through Genentech at the link below:
Actemra patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
ACTEMRA prescribing information can be found at the link below:
Information regarding ACTEMRA’s side effects can be found at MedlinePlus